TrialJournal of diabetes investigation2018

Efficacy and safety of once-weekly oral trelagliptin switched from once-daily dipeptidyl peptidase-4 inhibitor in patients with type 2 diabetes mellitus: An open-label, phase 3 exploratory study.

Nobuya Inagaki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.